Meeting
2013 Genitourinary Cancers Symposium
Real-world treatment patterns in third-line patients with metastatic renal cell carcinoma (mRCC): The changing landscape in the United States.
Authors
Sumanta Kumar Pal
City of Hope, Duarte, CA
Sumanta Kumar Pal , Elisabetta Malangone , Sharvari Bhurke , Magdaliz Gorritz , Lee Stern , John Coombs , James D. Turnbull , Xufang Wang , Zhimei Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 390)
DOI
10.1200/jco.2013.31.6_suppl.390
Abstract #
390
Poster Bd #
D11
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Association of high cost sharing and target therapy initiation among Medicare patients with metastatic renal cell carcinoma.
First Author: Pengxiang Li
Poster
2012 Genitourinary Cancers Symposium
Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
First Author: Jiahuai Tan
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi
Poster
2016 Genitourinary Cancers Symposium
RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.
First Author: Thomas Cosgriff